Literature DB >> 16621368

Inhibitory effects of statins on human monocarboxylate transporter 4.

Masaki Kobayashi1, Yukio Otsuka, Shirou Itagaki, Takeshi Hirano, Ken Iseki.   

Abstract

Human MCT4 (SLC16A3) is responsible for the efflux of L-lactic acid from skeletal muscle cells and is essential for muscle homeostasis. However, the effects of monocarboxylate drugs, such as statins on the MCT4-mediated transport of L-lactic acid have not been elucidated. Inhibition of L-lactic acid transport mediated by MCT4 might to lead to collapse of muscle homeostasis. The aim of this study was to establish an MCT4 transfected cell line and to clarify the transport mechanism of L-lactic acid and the effects of statins on this transport system. Results of Western blot analyses and immunohistochemistry studies indicated that the expression of CD147 and MCT4-FLAG protein were observed and was displayed clear plasma membrane localization in CD147 and MCT4-FLAG co-transfected cell line (cm cells). Uptake of L-lactic acid in cm cells was significantly greater than that in cells transfected with a vector alone. L-lactic acid uptake was concentration-dependent with a K(m) value of 28.43+/-3.87 mM. The results of a previous study showing a K(m) value of 28.5 mM in hMCT4-expressed oocytes. Lipophilic statins significantly inhibited [(14)C] L-lactic acid uptake in a concentration-dependent manner. In contrast, the inhibitory effects of hydrophilic statins were very weak.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621368     DOI: 10.1016/j.ijpharm.2006.02.043

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  21 in total

Review 1.  Role of monocarboxylate transporters in human cancers: state of the art.

Authors:  Céline Pinheiro; Adhemar Longatto-Filho; João Azevedo-Silva; Margarida Casal; Fernando C Schmitt; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 2.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

3.  Targeted sensitization of tumor cells for radiation through monocarboxylate transporters 1 and 4 inhibition in vitro.

Authors:  Gregor Brandstetter; Sebastian Blatt; Jutta Goldschmitt; Louise Taylor; Paul Heymann; Bilal Al-Nawas; Thomas Ziebart
Journal:  Clin Oral Investig       Date:  2020-06-03       Impact factor: 3.573

4.  Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies.

Authors:  Xiaowan Zheng; Lei Diao; Sean Ekins; James E Polli
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

Review 5.  Mechanisms and assessment of statin-related muscular adverse effects.

Authors:  Dirk Moßhammer; Elke Schaeffeler; Matthias Schwab; Klaus Mörike
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 6.  Statins and neuroprotection: basic pharmacology needed.

Authors:  W Gibson Wood; Walter E Mΰller; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2014-01-29       Impact factor: 5.590

Review 7.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

8.  Decreased astroglial monocarboxylate transporter 4 expression in temporal lobe epilepsy.

Authors:  Bei Liu; Le Niu; Ming-Zhi Shen; Lei Gao; Chao Wang; Jie Li; Li-Jia Song; Ye Tao; Qiang Meng; Qian-Li Yang; Guo-Dong Gao; Hua Zhang
Journal:  Mol Neurobiol       Date:  2014-01-25       Impact factor: 5.590

Review 9.  Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid.

Authors:  Marilyn E Morris; Melanie A Felmlee
Journal:  AAPS J       Date:  2008-06-04       Impact factor: 4.009

Review 10.  Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease.

Authors:  Melanie A Felmlee; Robert S Jones; Vivian Rodriguez-Cruz; Kristin E Follman; Marilyn E Morris
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.